ArticleFrontiers in immunology2025
The landscape and clinical impact of tumor-associated macrophages and PD-L1 in primary breast cancers and their brain metastases.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune architecture of colorectal cancer brain metastases: spatial TAM heterogeneity and PD-L1 dynamics.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumor-associated macrophages (TAMs) influence the tumor microenvironment and can contribute to tumor progression. They can polarize into M1 (classically activated) or M2 (alternatively activated) phenotype, which exhibit divergent functional characteristics. The comparison of TAMs between primary breast cancer (BC) and corresponding brain metastases (BMs) remains insufficiently explored and is the focus of this study. Methods: This study aimed to compare the infiltration of TAMs and PD-L1 expression in primary breast cancer and their brain metastases, by analyzing 27 paired samples and 26 additional brain metastases. Immunohistochemical staining was performed for the following markers: CD68, CD86 (M1), CD163 (M2), and PD-L1. Results: CD68 showed significantly higher expression levels in brain metastases compared to the corresponding primary breast cancers. In contrast, the expression of CD86 and CD163 showed comparable results between the primary tumors and their brain metastatic counterparts. Macrophages were consistently found to be more frequently present in the tumor stroma compared to the tumor nest. Survival analysis of the primary revealed that high expression of CD163 was associated with a recurrence-free survival. (RFS). Conversely, high expression of CD86 in brain metastases was associated with longer overall survival. Low expression of CD68 and CD163 in brain metastases correlated with the presence of meningeal carcinomatosis. The expression of PD-L1 in the primary tumor did not necessarily reflect the status of PD-L1 in the corresponding brain metastases. Conclusions: Overall, this study highlights the complex influence of TAMs on the course of primary breast cancers and their brain metastases. The discordant expression of the immune checkpoint molecule PD-L1 underscores the importance of evaluating the PD-L1 status in cerebral metastases to guide potential immunotherapeutic approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.